Back to Agenda
[V6-S1] What is Needed for Further Promotion of Drug Discovery and Development from Academia?
Session Chair(s)
Masaru Iwasaki, MD, PhD
Vice President, Head of Center for Advancing Clinical Research (CACR)
University of Yamanashi, Japan
It has been more than one year since AMED was established with the goal of promoting the commercialization of innovative seeds from academia. After AMED’s establishment, new efforts beyond the conventional framework were started. Although certain results are achieved, there still remain further challenges in advancing drug discovery and development from academia. In this session, experts from each stakeholder (AMED, academia, pharmaceutical companies, PMDA) will discuss the issues to be addressed and measures which further promote drug discovery and development from academia.
Speaker(s)
How and What to Develop, Innovate and Advance AMED
Ken Ishii, MD, PhD
Japan Agency for Medical Research and Development (AMED), Japan
Director, Department of Research Promotion
Strategy to Boost Drug Discovery and Development from Academia; What’s the Issue?
Yoichi Nakanishi, MD, PhD
Kyushu University, Japan
Professor and Director, Research Institute for Diseases of Chest
Companies and Drug Discovery by Academia
Jin Shiomura
Nobelpharma Co., Ltd., Japan
Managing Director and Chief Executive Officer
Pharmaceutical Affairs Consultation on R&D Strategy (Yakuzi-senryaku-Consultation) & SAKIGAKE (Review of Breakthrough products)
Noriatsu Kono, MPharm
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Organizational management
Have an account?